Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells

Molecular Cancer Research

Volumn 7, Issue 9, 2009, Pages 1497-1509

  Huang, Baoying ^a   Deo, Dayanand ^a   Xia, Mingxuan ^a   Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; NUTLIN 3; PROTEIN P107; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL AGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL AGING; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; EPITHELIAL CELLS; HCT116 CELLS; HUMANS; IMIDAZOLES; NEOPLASMS; PHENOTYPE; PIPERAZINES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349492724     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0144     Document Type: Article

References (36)

1. Hayflick L. The limited in vitro lifetime of human diploid cells. Exp Cell Res 1965;37:614-636
2. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-9367
3. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-2715 (Pubitemid 36667137)
4. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-2933
5. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005;37:961-976 (Pubitemid 40311739)
6. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-740
7. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-522 (Pubitemid 40269765)
8. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642. (Pubitemid 41117258)
9. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-660 (Pubitemid 46232886)
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310
11. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908
12. Lundberg AS, Hahn WC, Gupta P, Weinberg RA. Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000;12:705-709
13. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003;22:4212-4222 (Pubitemid 37021749)
14. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003;278:11731-11734 (Pubitemid 36800139)
15. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 2001;3:E277-86.
16. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848
17. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007;13:23-31.
18. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
19. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-1893 (Pubitemid 43228788)
20. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 2007;67:7350-7357 (Pubitemid 47206565)
21. Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008;68:3193-3203
22. Vassilev LT. Small-molecule antagonists of p53-2 binding: research tools and potential therapeutics. Cell Cycle 2004;3:419-421
23. Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT. Elevated MDM2 boosts the apoptotic activity of p53-2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008;7:1604-1612 (Pubitemid 351881328)
24. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1phase progression. Genes Dev 1999;13:1501-1512
25. Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T, Pellicer A. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 2000;20:2915-2925 (Pubitemid 30183511)
26. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 1996;93:13742-13747 (Pubitemid 26424190)
27. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-1501 (Pubitemid 28538613)
28. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000;35:317-329 (Pubitemid 30314689)
29. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-716 (Pubitemid 36724935)
30. Broude EV, Swift ME, Vivo C, et al. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 2007;26:6954-6958
31. Jackson JG, Pereira-Smith OM. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 2006;26:2501-2510
32. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004;279:53015-53022 (Pubitemid 40051800)
33. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006;8:877-884 (Pubitemid 44151592)
34. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007;1775:5-20.
35. Helmbold H, Deppert W, Bohn W. Regulation of cellular senescence by Rb2/p130. Oncogene 2006;25:5257-5262
36. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006;66:9646-9655 (Pubitemid 44623664)